SEARCH:   Advanced

Blood, 28 May 2009, Vol. 113, No. 22, pp. 5401-5411. Prepublished online as a Blood First Edition Paper on April 6, 2009; DOI 10.1182/blood-2008-12-196543. This Article Full Text Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2008-12-196543v1 113/22/5401    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Noens, L. Articles by Abraham, I. Search for Related Content PubMed PubMed Citation Articles by Noens, L. Articles by Abraham, I. Related Collections Free Research Articles Myeloid Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study Lucien Noens1, Marie-Anne van Lierde2, Robrecht De Bock3, Gregor Verhoef4, Pierre Zachée5, Zwi Berneman6, Philippe Martiat7, Philippe Mineur8, Koen Van Eygen9, Karen MacDonald10, Sabina De Geest11, Tara Albrecht10,12, and Ivo Abraham10,13 1 Universitair Ziekenhuis (UZ) Gent, Gent, Belgium; 2 Novartis Pharma, Vilvoorde, Belgium; 3 Ziekenhuisnetwerk Antwerpen (ZNA) Middelheim, Antwerpen, Belgium; 4 UZ Gasthuisberg, Leuven, Belgium; 5 ZNA Stuivenberg, Antwerpen, Belgium; 6 UZ Antwerpen, Antwerpen, Belgium; 7 Institut Jules Bordet, Bruxelles, Belgium; 8 Hôpital St Joseph, Gilly, Belgium; 9 Algemeen Ziekenhuis Groeninge, Kortrijk, Belgium; 10 Matrix45; Earlysville, VA; 11 Institute of Nursing Science, University of Basel, Basel, Switzerland; 12 School of Nursing, University of Virginia, Charlottesville; 13 College of Nursing, and Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Tucson Imatinib mesylate (imatinib) has been shown to be highly efficacious in the treatment of chronic myeloid leukemia (CML). Continuous and adequate dosing is essential for optimal outcomes and with imatinib treatment possibly being lifelong, patient adherence is critical. The ADAGIO (Adherence Assessment with Glivec: Indicators and Outcomes) study aimed to assess prospectively over a 90-day period the prevalence of imatinib nonadherence in patients with CML; to develop a multivariate canonical correlation model of how various determinants may be associated with various measures of nonadherence; and to examine whether treatment response is associated with adherence levels. A total of 202 patients were recruited from 34 centers in Belgium, of whom 169 were evaluable. One-third of patients were considered to be nonadherent. Only 14.2% of patients were perfectly adherent with 100% of prescribed imatinib taken. On average, patients with suboptimal response had significantly higher mean percentages of imatinib not taken (23.2%, standard deviation [SD] = 23.8) than did those with optimal response (7.3%, SD = 19.3, P = .005; percentages calculated as proportions x 100). Nonadherence is more prevalent than patients, physicians, and family members believe it is, and therefore should be assessed routinely. It is associated with poorer response to imatinib. Several determinants may serve as alert signals, many of which are clinically modifiable. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020